With 1.5 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.71 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.15 whereas the lowest price it dropped to was $5.51. The 52-week range on HYPD shows that it touched its highest point at $75.18 and its lowest point at $0.85 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 2.56.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HYPD was up-trending over the past week, with a rise of 5.37%, but this was down by -40.75% over a month. Three-month performance surged to 572.07% while six-month performance rose 265.69%. The stock lost -36.13% in the past year, while it has lost -89.98% so far this year.
Float and Shares Shorts:
At present, 5.60 million HYPD shares are outstanding with a float of 4.99 million shares on hand for trading. On 2025-07-15, short shares totaled 0.34 million, which was 637.0000000000001 higher than short shares on 1748563200. In addition to Mr. Michael M. Rowe as the firm’s Principal Financial Officer, CEO, President & Acting Chairman of the Board, Mr. Hyunsu Jung serves as its Chief Investment Officer & Director.
Institutional Ownership:
Through their ownership of 0.13434 of HYPD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, HYPD reported revenue of $14720.0 and operating income of -$3030693.0. The EBITDA in the recently reported quarter was -$2991657.0 and diluted EPS was -$1.59.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0 being high and $0 being low. For HYPD, this leads to a yearly average estimate of $0.
